A Phase Ia/Ib, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Patients With Lung Fibrosis or Liver Fibrosis
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2019
At a glance
- Drugs BLD-2660 (Primary)
- Indications Fibrosis; Hepatic fibrosis; Pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Blade Therapeutics
- 14 Jan 2019 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
- 17 Jul 2018 According to a Blade Therapeutics media release, results are expected by the fourth quarter of 2018.